A Medical Device Daily Staff Report
Imagine Eyes (Orsay, France) received CE mark approval to market its rtx1 retinal camera, a device designed to image the retina at the cellular scale, which help clinicians observe the micro vascular structures that are frequently affected by vision-degrading diseases.
The rtx1 retinal camera, which is focused at the retina's cone photoreceptor layer to avoid image blurring, is the 1st adaptive optics platform system approved for clinical use, the company said.
"The technology is protected by 4 proprietary patents," director of global communications Mark Zacharria said in prepared remarks. "These cover different aspects of the device's optical architecture that enable its superior image quality."
The rtx1 retinal camera features flood illumination similar to a existing cameras, and can capture vascular patterns in the eye to generate images alongside other diagnostic techniques, such as fundus imaging or OCT.
Besides the regulatory win in the European Union, the rtx1 has received the Shonin mark in Japan. The device will land FDA clearance "hopefully by the end of Q2 2013," and receive other regulatory approvals in the emerging market, Zacharria noted.
Surgical theater designer SKP is bought
Monitor Clipper Partners (Cambridge, Massachusetts), a private equity firm, and Augusto Orsini, an executive with over 25 years of experience in the surgical theater solutions market, reported their joint acquisition of Sengewald Klinikprodukte (SKP; Rohrdorf, Germany). SKP is a producer of drapes, gowns, and custom procedure trays for surgical theaters. The company's products are currently used in around 1 .5million surgical interventions annually throughout the world. The transaction includes SKP's subsidiaries, MSP Schmeiser (Horb am Neckar, Germany) and Texsan Medical EOOD (Sandanski, Bulgaria.) Concurrent with the acquisition, the new owners have also announced that Dieter Gruber has been named as managing director of SKP.
The acquisition was completed through a new parent company formed by MCP and Orsini, STS Medical Group (Luxembourg). STS Medical Group, which will be run by Orsini, will pursue a strategy to acquire additional businesses that provide products and services to surgical theaters, with SKP acting as the cornerstone acquisition for the group.
"SKP is a successful international medical products business with an over 30-year history of high-quality manufacturing, and our primary goal is to continue to meet the growing needs of SKP's existing customer base. Moreover, the company provides an ideal platform for STS Medical Group to develop an innovative player in the surgical theater solutions market," said Orsini, who is also a major shareholder of AEM Biotech, a healthcare investment and consulting firm. "Building on SKP's strong operational capabilities, we believe that we can pursue a strategy of aggressive international growth."
Accuray continues global expansion
Accuray (Sunnyvale, California) said Medanta – The Medicity Cancer Institute, and the Roentgen-BLK Super Speciality Hospital both recently acquired and started treating patients with the CyberKnife® VSI system, the solution for full-body radiosurgery marking the first-in-country CyberKnife VSI Systems in India.
Cancer incidence is growing in India with 900,000 new cancer cases and 400,000 cancer deaths annually. Cancers account for eight percent of total deaths in India thus creating a larger demand for cancer treatments.
By enriching their therapeutic offerings in radiation oncology, Medanta – The Medicity Cancer Institute and the Roentgen-BLK Radiation Oncology Center can now provide patients treatment with the CyberKnife System and expand the patient population that can now benefit from CyberKnife radiosurgery and stereotactic body radiation therapy (SBRT) in the region.
"The CyberKnife System is increasingly being used as an alternative to conventional radiation therapy in situations where its targeting accuracy allows a shorter and more intense course of radiation, including radiosurgery for brain tumors. We are pleased to have introduced this innovative technology at Medanta and look forward to witnessing the benefits that the System offers, including real-time tracking with automatic correction of tumors that move throughout the body. The CyberKnife System comes as a significant development in cancer therapy for patients as well as doctors as it offer the most precise treatment option for a wide range of patients," said Naresh Trehan, MD, chairman and managing director of Medanta – The Medicity.
The CyberKnife system delivers fractionated high precision radiation therapy with robotic intensity-modulated radiotherapy (IMRT) that can be delivered anywhere in the body, including intracranial, head and neck, spine, lung, liver and prostate.
Medanta – The Medicity is one of India's largest multi-super specialty institutes located in Gurgaon. The BLK Super Speciality Hospital's Cancer Center is a cancer centers in Northern India.